Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C mutant cancers

Added 113 days ago (28.01.2022)
Authors: Khan, H. Y., Nagasaka, M., Li, Y., Aboukameel, A., Uddin, M. H., Sexton, R., Bannoura, S., Mzannar, Y., Al-Hallak, M. N., Kim, S., Beydoun, R., Landesman, Y., Mamdani, H., Uprety, D., Philip, P. A., Mohammad, R., Shields, A., Azmi, A. S.
Source: bioRxiv
Read article